# NEW ISSUE ALERT Read about the clinical considerations of cannabis use in the inpatient … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/new-issue-alert-read-about-the-clinical-considerations-of-cannabis-use-in-the-inpatient/ > **Published:** 2026-06-01T21:42:59-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:30:29-04:00 > **Clinical Summary:** Clinical guide to cannabis use inpatient medical management, including withdrawal, interactions, and safe deprescribing protocols. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. Mental HealthSafetyResearchTHCCBDAnxietyDosing Why This Matters Clinicians need guidance on managing [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in hospitalized patients because withdrawal symptoms, drug interactions, and psychiatric complications can complicate medical and surgical care. Understanding inpatient cannabis management protocols helps providers optimize pain control, reduce agitation, and prevent adverse events during acute illness when patients cannot use cannabis. This knowledge enables clinicians to have informed conversations with patients about their [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) history and develop safer treatment plans that account for cannabis’s effects on medications and mental health. Clinical Summary This article addresses the clinical management of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in hospitalized medical patients, an increasingly common scenario as [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) expands and use rates rise among diverse patient populations. Understanding [cannabis pharmacology](https://cedclinic.com/cannabis-tolerance-behavioral-models/) and acute effects is essential for inpatient physicians, as cannabis use can complicate anesthesia management, interact with other medications, and exacerbate psychiatric or medical conditions during acute illness. The inpatient setting presents unique challenges including withdrawal symptoms, drug interactions, and the need to assess whether cannabis use contributed to the presenting condition or may interfere with treatment. Clinicians managing hospitalized patients should systematically screen for cannabis use, document frequency and route of administration, and anticipate potential complications including [cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome, drug interactions with sedatives or opioids, and psychiatric decompensation. A practical approach for hospitalized patients includes symptom-directed management of withdrawal, adjustment of pain and anxiety protocols to account for tolerance, and clear communication with the patient about cessation during hospitalization and discharge planning. Dr. Caplan’s Take “When a patient presents to the hospital with an acute medical or psychiatric condition, we need to know their cannabis use history with the same rigor we assess alcohol or opioids, because withdrawal and drug interactions are real clinical problems we’re not yet systematizing in most inpatient settings.” Clinical Perspective As [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) expands across jurisdictions, hospitalized patients increasingly present with active use or withdrawal concerns, yet clinical guidelines for inpatient management remain inconsistent and evidence-based protocols are limited. Healthcare providers should recognize that cannabis-related presentations span a spectrum from acute psychosis and [cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome to withdrawal-related anxiety and insomnia, each requiring distinct assessment and management strategies tailored to the patient’s underlying psychiatric and medical comorbidities. The complexity is heightened by variable THC potency in modern products, individual differences in metabolism and prior use patterns, and the frequent co-occurrence of cannabis with other substances or untreated mental illness, making attribution of symptoms challenging. Rather than viewing cannabis use categorically as either benign or uniformly harmful, clinicians should screen hospitalized patients for cannabis use during intake, document frequency and product type when possible, and monitor for both intoxication effects and withdrawal symptoms during the 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/mental-health/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20NEW%20ISSUE%20ALERT%20%20%20Read%20about%20the%20clinical%20considerations%20of%20cannabis%20use%20in%20the%20inpatient%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57205)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57205)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20NEW%20ISSUE%20ALERT%20%20%20Read%20about%20the%20clinical%20considerations%20of%20cannabis%20use%20in%20the%20inpatient%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57205)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Federal Cannabis Reform in Motion: What Businesses Need to Know | Ice Miller – JDSupra](https://cedclinic.com/federal-cannabis-reform-medical-implications-healthcare/) - Branford industrial site sold, to become cannabis growing operation – New Haven Register - [The Secret Ingredients Of Dr. Oz’s CBD Gummies: Unveiling The Mystery (Spoiler Alert](https://cedclinic.com/cbd-gummies-male-enhancement-marketing-concerns/) 📰 Source: [https://x.com/PsychiatricNews/status/2061433160773116192](https://x.com/PsychiatricNews/status/2061433160773116192) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).